1. Home
  2. INLX vs OTLK Comparison

INLX vs OTLK Comparison

Compare INLX & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INLX
  • OTLK
  • Stock Information
  • Founded
  • INLX 1996
  • OTLK 2010
  • Country
  • INLX United States
  • OTLK United States
  • Employees
  • INLX N/A
  • OTLK N/A
  • Industry
  • INLX EDP Services
  • OTLK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • INLX Technology
  • OTLK Health Care
  • Exchange
  • INLX Nasdaq
  • OTLK Nasdaq
  • Market Cap
  • INLX 53.5M
  • OTLK 48.3M
  • IPO Year
  • INLX N/A
  • OTLK 2016
  • Fundamental
  • Price
  • INLX $13.65
  • OTLK $2.03
  • Analyst Decision
  • INLX
  • OTLK Strong Buy
  • Analyst Count
  • INLX 0
  • OTLK 5
  • Target Price
  • INLX N/A
  • OTLK $9.60
  • AVG Volume (30 Days)
  • INLX 12.7K
  • OTLK 853.0K
  • Earning Date
  • INLX 08-12-2025
  • OTLK 08-13-2025
  • Dividend Yield
  • INLX N/A
  • OTLK N/A
  • EPS Growth
  • INLX N/A
  • OTLK N/A
  • EPS
  • INLX N/A
  • OTLK 0.83
  • Revenue
  • INLX $17,758,634.00
  • OTLK N/A
  • Revenue This Year
  • INLX $7.58
  • OTLK N/A
  • Revenue Next Year
  • INLX N/A
  • OTLK $419.06
  • P/E Ratio
  • INLX N/A
  • OTLK $2.50
  • Revenue Growth
  • INLX 3.21
  • OTLK N/A
  • 52 Week Low
  • INLX $6.95
  • OTLK $0.87
  • 52 Week High
  • INLX $16.50
  • OTLK $9.25
  • Technical
  • Relative Strength Index (RSI)
  • INLX 52.38
  • OTLK 66.41
  • Support Level
  • INLX $11.93
  • OTLK $1.56
  • Resistance Level
  • INLX $13.10
  • OTLK $2.00
  • Average True Range (ATR)
  • INLX 0.52
  • OTLK 0.13
  • MACD
  • INLX 0.13
  • OTLK 0.03
  • Stochastic Oscillator
  • INLX 75.20
  • OTLK 95.88

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: